Global Vaginitis Therapeutics Market to Reach $4.4 Billion by 2027

14 Mar 2021
www.globenewswire.com
Collaborate
New York, March 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaginitis Therapeutics Industry" - In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: - Global Vaginitis Therapeutics Market to Reach $4.4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Vaginitis Therapeutics estimated at US$2.7 Billion in the year 2020, is projected to reach a revised size of US$4.4 Billion by 2027, growing at a CAGR of 7.1% over the analysis period 2020-2027. Anti-Bacterial, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anti-Fungal segment is readjusted to a revised 7.2% CAGR for the next 7-year period. - The U.S. Market is Estimated at $735 Million, While China is Forecast to Grow at 10.8% CAGR - The Vaginitis Therapeutics market in the U.S. is estimated at US$735 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$965.9 Million by the year 2027 trailing a CAGR of 10.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 6.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR. - Hormone Segment to Record 7.4% CAGR - In the global Hormone segment, USA, Canada, Japan, China and Europe will drive the 6.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$428.8 Million in the year 2020 will reach a projected size of US$680.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$604 Million by the year 2027, while Latin America will expand at a 8.8% CAGR through the analysis period. Select Competitors (Total 42 Featured) - Bayer AG Janssen Pharmaceuticals Inc. Lumavita AG Lupin Pharmaceuticals Inc. Merck & Co., Inc. Mission Pharmacal Company Novartis AG Pfizer Inc. Symbiomix Therapeutics LLC Teva Pharmaceutical Industries Ltd Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Vaginitis Therapeutics Competitor Market Share Scenario Worldwide (in %): 2020E Global Competitor Market Shares by Segment 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Vaginitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Anti-Bacterial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Anti-Bacterial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Anti-Bacterial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Anti-Fungal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Prescription (Rx) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Prescription (Rx) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Prescription (Rx) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Over-the-Counter (OTC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Market Facts & Figures Market Analytics Table 19: USA Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 20: USA Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: USA 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 22: USA Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 23: USA Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: USA 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 CANADA Table 25: Canada Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: Canada Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: Canada 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 28: Canada Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: Canada Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: Canada 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 JAPAN Table 31: Japan Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Japan Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Japan 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 34: Japan Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: Japan Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: Japan 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 CHINA Table 37: China Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: China Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: China 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 40: China Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: China Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: China 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures Market Analytics Table 43: Europe Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 44: Europe Historic Review for Vaginitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: Europe 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 46: Europe Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: Europe Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: Europe 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 49: Europe Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 FRANCE Table 52: France Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: France Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: France 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 55: France Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: France Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: France 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 GERMANY Table 58: Germany Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: Germany Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: Germany 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 61: Germany Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: Germany Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: Germany 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 ITALY Table 64: Italy Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Italy Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Italy 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 67: Italy Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Italy Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Italy 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 70: UK Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: UK Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: UK 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 73: UK Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: UK Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: UK 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 SPAIN Table 76: Spain Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: Spain Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: Spain 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 79: Spain Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: Spain Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: Spain 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 RUSSIA Table 82: Russia Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Russia Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Russia 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 85: Russia Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Russia Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Russia 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 REST OF EUROPE Table 88: Rest of Europe Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Rest of Europe Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Rest of Europe 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 91: Rest of Europe Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Rest of Europe Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Rest of Europe 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 94: Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 95: Asia-Pacific Historic Review for Vaginitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 97: Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Asia-Pacific Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 100: Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 AUSTRALIA Table 103: Australia Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Australia Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Australia 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 106: Australia Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Australia Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Australia 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 INDIA Table 109: India Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: India Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: India 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 112: India Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: India Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: India 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 SOUTH KOREA Table 115: South Korea Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: South Korea Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: South Korea 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 118: South Korea Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: South Korea Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: South Korea 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 121: Rest of Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: Rest of Asia-Pacific Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 123: Rest of Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 124: Rest of Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 125: Rest of Asia-Pacific Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 126: Rest of Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 LATIN AMERICA Table 127: Latin America Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 128: Latin America Historic Review for Vaginitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 129: Latin America 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 Table 130: Latin America Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 131: Latin America Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 132: Latin America 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 133: Latin America Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 134: Latin America Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 135: Latin America 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 ARGENTINA Table 136: Argentina Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 137: Argentina Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 138: Argentina 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 139: Argentina Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 140: Argentina Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 141: Argentina 15-Year Perspective for Vaginitis Please contact our Customer Support Center to get the complete Table of Contents Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.